Novo Nordisk Picks Up Forma Therapeutics for $1.1 Billion

Novo Nordisk has reached an agreement to acquire Forma Therapeutics for $1.1 billion. A key therapeutic Novo Nordisk will acquire with the purchase is etavopivat, Forma’s drug candidate for sickle cell disease (SCD). The drug is being developed to help treat the anemia and damage to red blood cells caused by the genetic disorder, which affects 17 million people globally.

According to Ludovic Helfgott, Novo Nordisk’s head of rare disease, “Novo Nordisk has worked for more than 40 years to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. By adding Forma’s differentiated approach to address unmet needs for patients, we are taking a step forward in enhancing our SCD pipeline. We have an ambition to build a leading portfolio with standalone and combination treatments to tackle the complications and underlying causes of sickle cell disease”

To read more, click here.

(Source: PM Live, September 2^nd, 2022)